Akero Therapeutics Inc. (NASDAQ:AKRO) stock’s Relative Strength Index (RSI) is 74.16, with weekly volatility at 9.71% and ATR at 2.50. The AKRO stock’s 52-week price range has touched low of $10.78 and a $35.30 high. Its shares traded higher over the last trading session, gaining 5.88% on 07/06/20. The shares fell to a low of $32.20 before closing at $34.96. Intraday shares traded counted 0.66 million, which was -161.93% lower than its 30-day average trading volume of 252.17K. AKRO’s previous close was $33.02 while the outstanding shares total 28.50M.
Investors have identified the Biotechnology company Akero Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.01 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Akero Therapeutics Inc. (AKRO) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 126218000 million total, with 8286000 million as their total liabilities.
Potential earnings growth for Akero Therapeutics Inc. (AKRO)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, Akero Therapeutics Inc. recorded a total of 12.38 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 55.47% coming in sequential stages and their sales for the third quarter reducing by -31.04%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent -12.38 million trying to sell their products during the last quarter, with the result yielding a gross income of 0.49 million. This allows shareholders to hold on to 28.50M with the revenue now reading -0.42 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (-0.60 cents a share).
Having a look at the company’s valuation, the company is expected to record -2.90 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on AKRO sounds very interesting.
Is the stock of AKRO attractive?
In related news, 10% Owner, venBio Global Strategic Fund I sold 4,603 shares of the company’s stock in a transaction that recorded on Jul 06. The sale was performed at an average price of 33.83, for a total value of 155,721. As the sale deal closes, the 10% Owner, venBio Global Strategic Fund I now sold 3,800 shares of the company’s stock, valued at 127,805. Also, 10% Owner, venBio Global Strategic Fund I sold 108,064 shares of the company’s stock in a deal that was recorded on Jul 01. The shares were price at an average price of 34.45 per share, with a total market value of 3,723,010. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.50%.
5 out of 5 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Akero Therapeutics Inc.. 0 analysts has assigned a Sell rating on the AKRO stock. The 12-month mean consensus price target for the company’s shares has been set at $53.40.